<DOC>
	<DOCNO>NCT01974297</DOCNO>
	<brief_summary>The purpose study compare combination atorvastatin/fenofibric acid 10/135mg atorvastatin 20mg monotherapy mixed hyperlipidemia lipid goal atorvastatin 10mg monotherapy .</brief_summary>
	<brief_title>Comparison Efficacy Safety AtorVastatin mOnotherapy v . Combination Atorvastatin/Fenofibric Acid</brief_title>
	<detailed_description>Study conduct accord standard operating procedure - The sponsor , investigator , person involve study study center facility conduct study accordance study protocol , standard operating procedure , Korea Good Clinical Pratice . Data quality control - In order ensure reliability study-related data appropriate processing , sponsor apply quality control step data handle Monitoring - In order confirm study conduct , record report accord study protocol International Conference Harmonization Good Clinical Practice ( ICH-GCP ) , sponsor CRO perform monitoring study procedure . In monitoring , monitor cross check description case report form , etc . study-related record source document confirm description accurate . Measures take cope adverse event report procedure - The investigator notify event sponsor Contract Research Organization ( CRO ) immediately ( within around 24 hour ) notice occurence serioius adverse event telephone , fax E-mail . The investigator complete submit serioius adverse event ( SAE ) report form contain information Institutional Review Board ( IRB ) . Data Management - In study , data collect electronic Case Report Form ( CRF ) - Data validation miss data manage computer program manual check .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipidemia , Familial Combined</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type V</mesh_term>
	<mesh_term>Lipidoses</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Fenofibric acid</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>patient age 20years old patient take atorvastatin 10mg 1 tab per day 8 week screen patient meet follow criterion 1 . Low density lipoproteinscholesterol level &lt; 130mg/dL 2 . 150mg/dL &lt; Triglyceride level &lt; 500mg/dL 3 . HDLcholesterol level &lt; 45mg/dL patient consent consent enrol study Allergic HMGCoA reductase inhibitor fibrates uncontrolled Hypertension unstable angina , myocardial infarction , transient ischemic attack uncontrolled diabetes thyroid disease myopathy , rhabdomyolysis history alcoholic chronic diarrhea , gastrointestinal disease malignant tumor patient pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Atorvastatin</keyword>
	<keyword>Fenofibric acid</keyword>
	<keyword>combination</keyword>
	<keyword>monotherapy</keyword>
</DOC>